NCT04342403Unknown不适用
Clinical Studies Network Research Trial: Development of an On-Line Sarcoidosis Assessment Platform (OSAP) to Validate Sarcoidosis Phenotypes and Monitor Disease Burden Longitudinally
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 350
- 试验地点
- 3
- 主要终点
- KSQ
研究概览
简要总结
Evaluate change of quality of life of sarcoiodosis patients over a six months using various quality of life instruments including a monthly smart phone app.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of sarcoidosis by established criteria.
- •Patient has completed pulmonary function tests (spirometry) as per standard of care at the enrollment visit.
- •Ability to understand and read English at least at a 7th grade level.
- •Have access to a computer, iPad, smart phone, or another electronic device that will support the on-line sarcoidosis assessment platform.
- •The subject is willing to wear a daily activity and sleep tracker wristband (Fitbit ™ wristband) for 6 months.
排除标准
- •Life expectancy of < 1 year.
结局指标
主要结局
KSQ
时间窗: 6 months
Change in KSQ
次要结局
- Forced Vital Capacity (FVC)(6 months)
- SAT(6 Months)
- Visual Analog Scale (VAS)(6 Months)
研究者
Robert P Baughman
Professor
University of Cincinnati
研究点 (3)
Loading locations...
相似试验
终止
不适用
Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan PatientsChronic Kidney Disease Stage VHemodialysisNCT01758289AbbVie (prior sponsor, Abbott)105
已完成
4 期
Use of Focalin for Fatigue in SarcoidosisSarcoidosisNCT00361387University of Cincinnati12
招募中
不适用
Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)SarcoidosisNCT06234384Foundation for Sarcoidosis Research6,833
Unknown
4 期
Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT02195453Shandong Cancer Hospital and Institute520
Unknown
不适用
Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot StudyRelapsed and/or Refractory Multiple MyelomaNCT03903406Multinational Center for Quality of Life Research, Russia40